Drugs / NX-13
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04862741 | May 2021 → Jun 2022 | ulcerative colitis | Landos Biopharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04458805 | Jul → Oct 2020 | ulcerative colitis | Landos Biopharma Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05785715 | Apr 2023 → May 2025 | ulcerative colitis | AbbVie | Terminated | Missed primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX-13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04458805 ↗ |
| Action | Activate | “NX-13 activation of NLRX1 reduces intracellular reactive oxygen species and decreases inflammation in animal models of colitis.” PMID 37952114 ↗ May 2024 |
| Route | Oral | “single oral dose” NCT04458805 ↗ |
| Target | NLRX1 | “NX-13 activation of NLRX1 reduces intracellular reactive oxygen species and decreases inflammation in animal models of colitis.” PMID 37952114 ↗ May 2024 |